-
1
-
-
0035656221
-
Dysregulation of intestinal mucosal immunity: Implications in inflammatory bowel disease
-
Laroux FS, Pavlick KP, Wolf RE, et al. Dysregulation of intestinal mucosal immunity: implications in inflammatory bowel disease. News Physiol Sci 2001; 16: 272-7
-
(2001)
News Physiol Sci
, vol.16
, pp. 272-277
-
-
Laroux, F.S.1
Pavlick, K.P.2
Wolf, R.E.3
-
2
-
-
0242330303
-
Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: A statewide population-based study
-
Kugathasan S, Judd RH, Hoffmann RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 2003; 143: 525-31
-
(2003)
J Pediatr
, vol.143
, pp. 525-531
-
-
Kugathasan, S.1
Judd, R.H.2
Hoffmann, R.G.3
-
3
-
-
0141534418
-
Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990-2001
-
Hildebrand H, Finkel Y, Grahnquist L, et al. Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990-2001. Gut 2003; 52: 1432-4
-
(2003)
Gut
, vol.52
, pp. 1432-1434
-
-
Hildebrand, H.1
Finkel, Y.2
Grahnquist, L.3
-
4
-
-
0034080053
-
Inflammatory bowel disease in children and adolescents in Sweden, 1984-1995
-
Lindberg E, Lindquist B, Holmquist L, et al. Inflammatory bowel disease in children and adolescents in Sweden, 1984-1995. J Pediatr Gastroenterol Nutr 2000; 30: 259-64
-
(2000)
J Pediatr Gastroenterol Nutr
, vol.30
, pp. 259-264
-
-
Lindberg, E.1
Lindquist, B.2
Holmquist, L.3
-
5
-
-
0027164338
-
Growth and clinical course of children with Crohn's disease
-
Griffiths AM, Nguyen P, Smith C, et al. Growth and clinical course of children with Crohn's disease. Gut 1993; 34: 939-43
-
(1993)
Gut
, vol.34
, pp. 939-943
-
-
Griffiths, A.M.1
Nguyen, P.2
Smith, C.3
-
6
-
-
0344946236
-
Presenting features of inflammatory bowel disease in Great Britain and Ireland
-
Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003; 88: 995-1000
-
(2003)
Arch Dis Child
, vol.88
, pp. 995-1000
-
-
Sawczenko, A.1
Sandhu, B.K.2
-
7
-
-
33745023161
-
Inflammatory bowel disease in children: A pediatrician's perspective
-
Cuffari C. Inflammatory bowel disease in children: a pediatrician's perspective. Minerva Pediatr 2006; 58: 139-57
-
(2006)
Minerva Pediatr
, vol.58
, pp. 139-157
-
-
Cuffari, C.1
-
8
-
-
22044445381
-
Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: Recommendations for diagnosis -the Porto criteria
-
IBD Working Group of the European Society for Paediatric Gastroenterology
-
IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis -the Porto criteria. J Pediatr Gastroenterol Nutr 2005; 41: 1-7
-
(2005)
J Pediatr Gastroenterol Nutr
, vol.41
, pp. 1-7
-
-
-
9
-
-
0033770169
-
A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn disease
-
Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn disease. Gastroenterology 2000; 119: 895-902
-
(2000)
Gastroenterology
, vol.119
, pp. 895-902
-
-
Markowitz, J.1
Grancher, K.2
Kohn, N.3
-
10
-
-
0034800239
-
Surpassing conventional therapies: The role of biologic therapy
-
Baldassano RN. Surpassing conventional therapies: the role of biologic therapy. J Pediatr Gastroenterol Nutr 2001; 33 Suppl. 1: S19-26
-
(2001)
J Pediatr Gastroenterol Nutr
, vol.33
, Issue.SUPPL. 1
-
-
Baldassano, R.N.1
-
11
-
-
33644877046
-
Early or late guided missile in the treatment of Crohn disease?
-
Caprilli R, Angelucci E, Cocco A. Early or late guided missile in the treatment of Crohn disease? Dig Liver Dis 2005; 37: 973-9
-
(2005)
Dig Liver Dis
, vol.37
, pp. 973-979
-
-
Caprilli, R.1
Angelucci, E.2
Cocco, A.3
-
12
-
-
4544313645
-
Managing immunogenic responses to infliximab: Treatment implications for patients with Crohn disease
-
Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn disease. Drugs 2004; 64: 1767-77
-
(2004)
Drugs
, vol.64
, pp. 1767-1777
-
-
Han, P.D.1
Cohen, R.D.2
-
13
-
-
33644892470
-
Infliximab therapy for inflammatory bowel disease: Seven years on
-
Rutgeerts P, Van Assche G, Vermeire S. Infliximab therapy for inflammatory bowel disease: seven years on. Aliment Pharmacol Ther 2006; 23: 451-63
-
(2006)
Aliment Pharmacol Ther
, vol.23
, pp. 451-463
-
-
Rutgeerts, P.1
Van Assche, G.2
Vermeire, S.3
-
15
-
-
33749443342
-
A randomized, multicenter, open-label study to evaluate the safety and efficacy of infliximab in pediatric patients with moderate-to-severe Crohn's disease [abstract]
-
Hyams J, Crandall W, Kugathasan S, et al. A randomized, multicenter, open-label study to evaluate the safety and efficacy of infliximab in pediatric patients with moderate-to-severe Crohn's disease [abstract]. J Pediatr Gastroenterol Nutr 2005; 41: 539
-
(2005)
J Pediatr Gastroenterol Nutr
, vol.41
, pp. 539
-
-
Hyams, J.1
Crandall, W.2
Kugathasan, S.3
-
16
-
-
0036288520
-
Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease
-
Brynskov J, Foegh P, Pedersen G, et al. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 2002; 51: 37-43
-
(2002)
Gut
, vol.51
, pp. 37-43
-
-
Brynskov, J.1
Foegh, P.2
Pedersen, G.3
-
17
-
-
0034020230
-
The importance of shedding of membrane proteins for cytokine biology
-
Mullberg J, Althoff K, Jostock T, et al. The importance of shedding of membrane proteins for cytokine biology. Eur Cytokine Netw 2000; 11: 27-38
-
(2000)
Eur Cytokine Netw
, vol.11
, pp. 27-38
-
-
Mullberg, J.1
Althoff, K.2
Jostock, T.3
-
18
-
-
0034075936
-
Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease
-
Louis E, Ribbens C, Godon A, et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 2000; 120: 241-6
-
(2000)
Clin Exp Immunol
, vol.120
, pp. 241-246
-
-
Louis, E.1
Ribbens, C.2
Godon, A.3
-
19
-
-
0028236232
-
Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease
-
Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106: 1455-66
-
(1994)
Gastroenterology
, vol.106
, pp. 1455-1466
-
-
Breese, E.J.1
Michie, C.A.2
Nicholls, S.W.3
-
20
-
-
0027186553
-
Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea
-
Nicholls S, Stephens S, Braegger CP, et al. Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathol 1993; 46: 757-60
-
(1993)
J Clin Pathol
, vol.46
, pp. 757-760
-
-
Nicholls, S.1
Stephens, S.2
Braegger, C.P.3
-
21
-
-
0036840888
-
Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytopheresis
-
Tsukada Y, Nakamura T, Iimura M, et al. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytopheresis. Am J Gastroenterol 2002; 97: 2820-8
-
(2002)
Am J Gastroenterol
, vol.97
, pp. 2820-2828
-
-
Tsukada, Y.1
Nakamura, T.2
Iimura, M.3
-
22
-
-
0036457057
-
Inflammatory bowel disease: New insights into pathogenesis and therapy
-
Ardizzone S, Porro G. Inflammatory bowel disease: new insights into pathogenesis and therapy. J Intern Med 2002; 252: 475-96
-
(2002)
J Intern Med
, vol.252
, pp. 475-496
-
-
Ardizzone, S.1
Porro, G.2
-
23
-
-
17744373658
-
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn disease
-
Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn disease. Aliment Pharmacol Ther 2001; 15: 463-73
-
(2001)
Aliment Pharmacol Ther
, vol.15
, pp. 463-473
-
-
Cornillie, F.1
Shealy, D.2
D'Haens, G.3
-
24
-
-
2442560241
-
Optimizing anti-TNF treatment in inflammatory bowel disease
-
Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-610
-
(2004)
Gastroenterology
, vol.126
, pp. 1593-1610
-
-
Rutgeerts, P.1
Van Assche, G.2
Vermeire, S.3
-
25
-
-
27644566447
-
Biologic therapy for inflammatory bowel disease
-
Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs 2005; 65: 2253-86
-
(2005)
Drugs
, vol.65
, pp. 2253-2286
-
-
Ardizzone, S.1
Bianchi Porro, G.2
-
26
-
-
4344700784
-
Downregulation of epithelial apoptosis and barrier repair in active Crohn disease by tumour necrosis factor-alpha antibody treatment
-
Zeissig S, Bojarski C, Buergel N, et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn disease by tumour necrosis factor-alpha antibody treatment Gut 2004; 53: 1295-1302
-
(2004)
Gut
, vol.53
, pp. 1295-1302
-
-
Zeissig, S.1
Bojarski, C.2
Buergel, N.3
-
27
-
-
33744546642
-
Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions
-
Begue B, Wajant H, Bambou JC, et al. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. Gastroenterology 2006; 130: 1962-74
-
(2006)
Gastroenterology
, vol.130
, pp. 1962-1974
-
-
Begue, B.1
Wajant, H.2
Bambou, J.C.3
-
28
-
-
0038047689
-
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn disease
-
Van den Brande JM, Braat H, van den Brink GP, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn disease. Gastroenterology 2003; 124: 1774-85
-
(2003)
Gastroenterology
, vol.124
, pp. 1774-1785
-
-
Van den Brande, J.M.1
Braat, H.2
van den Brink, G.P.3
-
29
-
-
0346461662
-
Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn disease
-
Di Sabatino A, Ciccocioppo R, Cinque B, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn disease. Gut 2004; 53: 70-7
-
(2004)
Gut
, vol.53
, pp. 70-77
-
-
Di Sabatino, A.1
Ciccocioppo, R.2
Cinque, B.3
-
30
-
-
0035053968
-
An engineered human antibody to TNF (CDP571) for active Crohn disease: A randomized double-bind, placebo-controlled trial
-
Sandborn WJ, Feagen BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn disease: a randomized double-bind, placebo-controlled trial. Gastroenterology 2001; 120: 1330-8
-
(2001)
Gastroenterology
, vol.120
, pp. 1330-1338
-
-
Sandborn, W.J.1
Feagen, B.G.2
Hanauer, S.B.3
-
31
-
-
9144261186
-
CDP571, a humanized anti-tumor necrosis factor-alpha monoclonal antibody in pediatric Crohn's disease
-
Mamula P, Cohen SA, Ferry GD, et al. CDP571, a humanized anti-tumor necrosis factor-alpha monoclonal antibody in pediatric Crohn's disease. Inflamm Bowel Dis 2004; 10: 723-30
-
(2004)
Inflamm Bowel Dis
, vol.10
, pp. 723-730
-
-
Mamula, P.1
Cohen, S.A.2
Ferry, G.D.3
-
32
-
-
0033778364
-
Tumor necrosis factor: Biology and therapeutic inhibitors
-
Papadakis CA, Targan SA. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000; 119: 1148-57
-
(2000)
Gastroenterology
, vol.119
, pp. 1148-1157
-
-
Papadakis, C.A.1
Targan, S.A.2
-
33
-
-
14044252848
-
Infliximab induces apoptosis of human monocytes: A comparative study with infliximab and etanercept
-
Shen C, Maerten P, Geboes K, et al. Infliximab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005; 21: 251-8
-
(2005)
Aliment Pharmacol Ther
, vol.21
, pp. 251-258
-
-
Shen, C.1
Maerten, P.2
Geboes, K.3
-
34
-
-
19144369300
-
Adalimumab induces apoptosis of human monocytes and T lymphocytes in a human-mouse chimeric model
-
Shen C, Van Assche G, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes and T lymphocytes in a human-mouse chimeric model. Clin Immunol 2005; 115: 250-9
-
(2005)
Clin Immunol
, vol.115
, pp. 250-259
-
-
Shen, C.1
Van Assche, G.2
Colpaert, S.3
-
35
-
-
32044474228
-
TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: A novel anti-inflammatory mechanism of infliximab in Crohn disease
-
Danese S, Sans M, Scaldaferri F, et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn disease. J Immunol 2006; 176: 2617-24
-
(2006)
J Immunol
, vol.176
, pp. 2617-2624
-
-
Danese, S.1
Sans, M.2
Scaldaferri, F.3
-
36
-
-
0036678630
-
Anti-tumor necrosis factor treatment restores the gut barrier in Crohn disease
-
Suenaert P, Bulteel V, Lemmens L, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn disease. Am J Gastroenterol 2002; 97: 2007-11
-
(2002)
Am J Gastroenterol
, vol.97
, pp. 2007-2011
-
-
Suenaert, P.1
Bulteel, V.2
Lemmens, L.3
-
37
-
-
0027231774
-
Tumour-necrosis-factor antibody treatment in Crohn disease
-
Derkx B, Taminiau J, Radema S, et al. Tumour-necrosis-factor antibody treatment in Crohn disease. Lancet 1993; 342: 173-4
-
(1993)
Lancet
, vol.342
, pp. 173-174
-
-
Derkx, B.1
Taminiau, J.2
Radema, S.3
-
38
-
-
0030954732
-
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn disease. Crohn Disease cA2 Study Group
-
Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn disease. Crohn Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35
-
(1997)
N Engl J Med
, vol.337
, pp. 1029-1035
-
-
Targan, S.R.1
Hanauer, S.B.2
van Deventer, S.J.3
-
39
-
-
0037018761
-
Maintenance infliximab for Crohn disease: The ACCENT I randomized trial
-
Hanauer SB, Feagen BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn disease: the ACCENT I randomized trial. Lancet 2002; 359: 1541-9
-
(2002)
Lancet
, vol.359
, pp. 1541-1549
-
-
Hanauer, S.B.1
Feagen, B.G.2
Lichtenstein, G.R.3
-
40
-
-
10744224387
-
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn disease
-
Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn disease. Gastroenterology 2004; 126: 402-13
-
(2004)
Gastroenterology
, vol.126
, pp. 402-413
-
-
Rutgeerts, P.1
Feagan, B.G.2
Lichtenstein, G.R.3
-
41
-
-
0038184193
-
Infliximab (REMICADE) therapy in the treatment of pediatric Crohn disease
-
Baldassano RN, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn disease. Am J Gastroenterol 2003; 98: 833-8
-
(2003)
Am J Gastroenterol
, vol.98
, pp. 833-838
-
-
Baldassano, R.N.1
Braegger, C.P.2
Escher, J.C.3
-
42
-
-
0033761188
-
Prolonged duration of response to infliximab in early but not late pediatric Crohn disease
-
Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn disease. Am J Gastroenterol 2000; 95: 3189-94
-
(2000)
Am J Gastroenterol
, vol.95
, pp. 3189-3194
-
-
Kugathasan, S.1
Werlin, S.L.2
Martinez, A.3
-
43
-
-
0034785611
-
Prolonged duration of response to infliximab in early pediatric Crohn disease
-
Kugathasan S. Prolonged duration of response to infliximab in early pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2001; 33 Suppl. 1: S40-3
-
(2001)
J Pediatr Gastroenterol Nutr
, vol.33
, Issue.SUPPL. 1
-
-
Kugathasan, S.1
-
44
-
-
0033842357
-
Use of infliximab in the treatment of Crohn disease in children and adolescents
-
Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn disease in children and adolescents. J Pediatr 2000; 137: 192-6
-
(2000)
J Pediatr
, vol.137
, pp. 192-196
-
-
Hyams, J.S.1
Markowitz, J.2
Wyllie, R.3
-
45
-
-
0141613187
-
A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn disease
-
Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003; 36: 632-6
-
(2003)
J Pediatr Gastroenterol Nutr
, vol.36
, pp. 632-636
-
-
Cezard, J.P.1
Nouaili, N.2
Talbotec, C.3
-
46
-
-
4544305960
-
Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn disease
-
Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn disease. Dig Liver Dis 2004; 36: 342-7
-
(2004)
Dig Liver Dis
, vol.36
, pp. 342-347
-
-
Borrelli, O.1
Bascietto, C.2
Viola, F.3
-
47
-
-
3543101018
-
Infliximab therapy in pediatric Crohn's pouchitis
-
Kooros K, Katz AJ. Infliximab therapy in pediatric Crohn's pouchitis. Inflamm Bowel Dis 2004; 10: 417-20
-
(2004)
Inflamm Bowel Dis
, vol.10
, pp. 417-420
-
-
Kooros, K.1
Katz, A.J.2
-
48
-
-
0032833517
-
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn disease
-
Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn disease. Gastroenterology 1999; 117: 761-9
-
(1999)
Gastroenterology
, vol.117
, pp. 761-769
-
-
Rutgeerts, P.1
D'Haens, G.2
Targan, S.3
-
49
-
-
14644440656
-
Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in The Netherlands
-
de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr 2004; 39: 46-52
-
(2004)
J Pediatr Gastroenterol Nutr
, vol.39
, pp. 46-52
-
-
de Ridder, L.1
Escher, J.C.2
Bouquet, J.3
-
50
-
-
16544374044
-
Infliximab: How to use it in pediatric Crohn disease
-
Ruemmele FM. Infliximab: how to use it in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2004; 39: 12-4
-
(2004)
J Pediatr Gastroenterol Nutr
, vol.39
, pp. 12-14
-
-
Ruemmele, F.M.1
-
51
-
-
0042329252
-
Response to infliximab is related to disease duration in paediatric Crohn disease
-
Lionetti P, Bronzini F, Salvestrini C. Response to infliximab is related to disease duration in paediatric Crohn disease. Aliment Pharmacol Ther 2003; 18: 425-31
-
(2003)
Aliment Pharmacol Ther
, vol.18
, pp. 425-431
-
-
Lionetti, P.1
Bronzini, F.2
Salvestrini, C.3
-
52
-
-
9144234882
-
Efficacy and tolerance of infliximab in children and adolescents with Crohn disease
-
Lamireau T, Cezard JP, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn disease. Inflamm Bowel Dis 2004; 10: 745-50
-
(2004)
Inflamm Bowel Dis
, vol.10
, pp. 745-750
-
-
Lamireau, T.1
Cezard, J.P.2
Dabadie, A.3
-
53
-
-
30344431805
-
Infliximab dependency in a national cohort of children with Crohn disease
-
Wewer V, Riis L, Vind I, et al. Infliximab dependency in a national cohort of children with Crohn disease. J Pediatr Gastroenterol Nutr 2006; 42: 40-5
-
(2006)
J Pediatr Gastroenterol Nutr
, vol.42
, pp. 40-45
-
-
Wewer, V.1
Riis, L.2
Vind, I.3
-
54
-
-
29444445950
-
Clinical and biological consequences of immunization to infliximab in pediatric Crohn disease
-
Candon S, Mosca A, Ruemmele F, et al. Clinical and biological consequences of immunization to infliximab in pediatric Crohn disease. Clin Immunol 2006; 118: 11-9
-
(2006)
Clin Immunol
, vol.118
, pp. 11-19
-
-
Candon, S.1
Mosca, A.2
Ruemmele, F.3
-
55
-
-
0033529049
-
Infliximab for the treatment of fistulas in patients with Crohn disease
-
Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn disease. N Engl J Med 1999; 340: 1398-405
-
(1999)
N Engl J Med
, vol.340
, pp. 1398-1405
-
-
Present, D.H.1
Rutgeerts, P.2
Targan, S.3
-
56
-
-
10744221312
-
Infliximab maintenance therapy for fistulizing Crohn disease
-
Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn disease. N Engl J Med 2004; 350: 876-85
-
(2004)
N Engl J Med
, vol.350
, pp. 876-885
-
-
Sands, B.E.1
Anderson, F.H.2
Bernstein, C.N.3
-
57
-
-
17144388945
-
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn disease
-
Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn disease. Gastroenterology 2005; 128: 862-9
-
(2005)
Gastroenterology
, vol.128
, pp. 862-869
-
-
Lichtenstein, G.R.1
Yan, S.2
Bala, M.3
-
58
-
-
33646883499
-
Maintenance infliximab does not result in increased abscess development in fistulizing Crohn disease: Results from the ACCENT II study
-
Sands BE, Blank MA, Diamond RH, et al. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn disease: results from the ACCENT II study. Aliment Pharmacol Ther 2006; 23: 1127-36
-
(2006)
Aliment Pharmacol Ther
, vol.23
, pp. 1127-1136
-
-
Sands, B.E.1
Blank, M.A.2
Diamond, R.H.3
-
59
-
-
5044235159
-
Long-term treatment of rectovaginal fistulas in Crohn disease: Response to infliximab in the ACCENT II Study
-
Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004; 2: 912-20
-
(2004)
Clin Gastroenterol Hepatol
, vol.2
, pp. 912-920
-
-
Sands, B.E.1
Blank, M.A.2
Patel, K.3
-
60
-
-
9144268929
-
Infliximab: Lack of efficacy on perforating complications in Crohn disease
-
Miehsler W, Reinisch W, Kazemi-Shirazi L, et al. Infliximab: lack of efficacy on perforating complications in Crohn disease. Inflamm Bowel Dis 2004; 10: 36-40
-
(2004)
Inflamm Bowel Dis
, vol.10
, pp. 36-40
-
-
Miehsler, W.1
Reinisch, W.2
Kazemi-Shirazi, L.3
-
61
-
-
33748675696
-
Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: A pilot study
-
Asteria CR, Ficari F, Bagnoli S, et al. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Scand J Gastroenterol 2006; 41: 1064-72
-
(2006)
Scand J Gastroenterol
, vol.41
, pp. 1064-1072
-
-
Asteria, C.R.1
Ficari, F.2
Bagnoli, S.3
-
63
-
-
33644921817
-
A case of refractory pediatric Crohn disease with a successful treatment by infliximab therapy
-
Park SH, Jeen YT, Chun HR, et al. A case of refractory pediatric Crohn disease with a successful treatment by infliximab therapy. Korean J Gastroenterol 2005; 46: 297-301
-
(2005)
Korean J Gastroenterol
, vol.46
, pp. 297-301
-
-
Park, S.H.1
Jeen, Y.T.2
Chun, H.R.3
-
64
-
-
33846635983
-
Infliximab in pediatric Crohn disease patients with enterovesicular fistulas
-
Teitelbaum JE, Saeed S, Triantafyllopoulou M, et al. Infliximab in pediatric Crohn disease patients with enterovesicular fistulas. J Ped Gastroent Nutr 2007; 44: 279-82
-
(2007)
J Ped Gastroent Nutr
, vol.44
, pp. 279-282
-
-
Teitelbaum, J.E.1
Saeed, S.2
Triantafyllopoulou, M.3
-
65
-
-
0037282938
-
Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn disease
-
Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn disease. Am J Gastroenterol 2003; 98: 332-9
-
(2003)
Am J Gastroenterol
, vol.98
, pp. 332-339
-
-
Van Assche, G.1
Vanbeckevoort, D.2
Bielen, D.3
-
66
-
-
0037325450
-
Response of fistulizing Crohn disease to infliximab treatment assessed by magnetic resonance imaging
-
Bell SJ, Halligan S, Windsor AC, et al. Response of fistulizing Crohn disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2003; 17: 387-93
-
(2003)
Aliment Pharmacol Ther
, vol.17
, pp. 387-393
-
-
Bell, S.J.1
Halligan, S.2
Windsor, A.C.3
-
67
-
-
0037348380
-
Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement
-
Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003; 9: 98-103
-
(2003)
Inflamm Bowel Dis
, vol.9
, pp. 98-103
-
-
Regueiro, M.1
Mardini, H.2
-
68
-
-
0034777502
-
Infliximab in the treatment of severe, corticosteroid-refractory ulcerative colitis: A pilot study
-
Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, corticosteroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 7: 83-8
-
(2001)
Inflamm Bowel Dis
, vol.7
, pp. 83-88
-
-
Sands, B.E.1
Tremaine, W.J.2
Sandborn, W.J.3
-
69
-
-
0038460945
-
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: A randomised controlled trial
-
Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 52: 998-1002
-
(2003)
Gut
, vol.52
, pp. 998-1002
-
-
Probert, C.S.1
Hearing, S.D.2
Schreiber, S.3
-
70
-
-
8444238193
-
Infliximab for acute, not corticosteroid-refractory ulcerative colitis: A randomized pilot study
-
Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not corticosteroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004; 16: 1167-71
-
(2004)
Eur J Gastroenterol Hepatol
, vol.16
, pp. 1167-1171
-
-
Ochsenkuhn, T.1
Sackmann, M.2
Goke, B.3
-
71
-
-
27644549042
-
State of the art: IBD therapy and clinical trials in IBD
-
Isaacs KL, Lewis JD, Sandborn WJ, et al. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis 2005; 11 Suppl. 1: S3-12
-
(2005)
Inflamm Bowel Dis
, vol.11
, Issue.SUPPL. 1
-
-
Isaacs, K.L.1
Lewis, J.D.2
Sandborn, W.J.3
-
72
-
-
28844473957
-
Infliximab for induction and maintenance therapy for ulcerative colitis
-
Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-76
-
(2005)
N Engl J Med
, vol.353
, pp. 2462-2476
-
-
Rutgeerts, P.1
Sandborn, W.J.2
Feagan, B.G.3
-
73
-
-
20444479336
-
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study
-
Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11
-
(2005)
Gastroenterology
, vol.128
, pp. 1805-1811
-
-
Jarnerot, G.1
Hertervig, E.2
Friis-Liby, I.3
-
74
-
-
33750105599
-
Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis
-
CD005112
-
Lawson M, Thomas A, Akobeng A. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; (3): CD005112
-
(2006)
Cochrane Database Syst Rev
, Issue.3
-
-
Lawson, M.1
Thomas, A.2
Akobeng, A.3
-
77
-
-
15944366494
-
Infliximab efficacy in pediatric ulcerative colitis
-
Eidelwein AP, Cuffari C, Abadom V, et al. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 2005; 11: 213-8
-
(2005)
Inflamm Bowel Dis
, vol.11
, pp. 213-218
-
-
Eidelwein, A.P.1
Cuffari, C.2
Abadom, V.3
-
78
-
-
0034911830
-
Use of infliximab in pediatric patients with inflammatory bowel disease
-
Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, et al. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001; 35: 823-8
-
(2001)
Ann Pharmacother
, vol.35
, pp. 823-828
-
-
Serrano, M.S.1
Schmidt-Sommerfeld, E.2
Kilbaugh, T.J.3
-
79
-
-
0010612959
-
Infliximab therapy for pediatric ulcerative colitis [abstract]
-
Oliva-Hemker M, Roper S, Cuffari C, et al. Infliximab therapy for pediatric ulcerative colitis [abstract]. Gastroenterology 2002; 122: A616
-
(2002)
Gastroenterology
, vol.122
-
-
Oliva-Hemker, M.1
Roper, S.2
Cuffari, C.3
-
80
-
-
33847700853
-
Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis
-
Fanjiang G, Russell GH. Katz AJ. Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2007; 44: 312-7
-
(2007)
J Pediatr Gastroenterol Nutr
, vol.44
, pp. 312-317
-
-
Fanjiang, G.1
Russell, G.H.2
Katz, A.J.3
-
81
-
-
0028292007
-
Cyclosporine in severe ulcerative colitis refractory to steroid therapy
-
Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. New Engl J Med 1994; 330: 1841-5
-
(1994)
New Engl J Med
, vol.330
, pp. 1841-1845
-
-
Lichtiger, S.1
Present, D.H.2
Kornbluth, A.3
-
82
-
-
33847709966
-
Anti-tumour necrosis factor therapy for ulcerative colitis: Evidence to date
-
Thukral C, Cheifetz A, Peppercorn MA. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date. Drugs 2006; 66: 2059-65
-
(2006)
Drugs
, vol.66
, pp. 2059-2065
-
-
Thukral, C.1
Cheifetz, A.2
Peppercorn, M.A.3
-
83
-
-
0142091279
-
Infliximab in the treatment of medically refractory indeterminate colitis
-
Papadakis KA, Treyzon L, Abreu MT, et al. Infliximab in the treatment of medically refractory indeterminate colitis. Aliment Pharmacol Ther 2003; 18: 741-7
-
(2003)
Aliment Pharmacol Ther
, vol.18
, pp. 741-747
-
-
Papadakis, K.A.1
Treyzon, L.2
Abreu, M.T.3
-
84
-
-
0042128405
-
Infliximab for refractory ulcerative colitis or indeterminate colitis: An open-label multicentre study
-
Gornet JM, Couve S, Hassani Z, et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther 2003; 18: 175-81
-
(2003)
Aliment Pharmacol Ther
, vol.18
, pp. 175-181
-
-
Gornet, J.M.1
Couve, S.2
Hassani, Z.3
-
85
-
-
0041571851
-
Infliximab for treatment of Pyoderma gangrenosum associated with inflammatory bowel disease
-
Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of Pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1821-6
-
(2003)
Am J Gastroenterol
, vol.98
, pp. 1821-1826
-
-
Regueiro, M.1
Valentine, J.2
Plevy, S.3
-
86
-
-
33645128368
-
Infliximab for the treatment of Pyoderma gangrenosum: A randomised, double blind, placebo controlled trial
-
Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of Pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006; 55: 505-9
-
(2006)
Gut
, vol.55
, pp. 505-509
-
-
Brooklyn, T.N.1
Dunnill, M.G.2
Shetty, A.3
-
87
-
-
1542707085
-
Dermatologic manifestations of Crohn disease in children: Response to infliximab
-
Kugathasan S, Miranda A, Nocton J, et al. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 2003; 37: 150-4
-
(2003)
J Pediatr Gastroenterol Nutr
, vol.37
, pp. 150-154
-
-
Kugathasan, S.1
Miranda, A.2
Nocton, J.3
-
88
-
-
0036259538
-
Resolution of severe peristomal Pyoderma gangrenosum with infliximab in a child with Crohn disease
-
Batres LA, Mamula P, Baldassano RN. Resolution of severe peristomal Pyoderma gangrenosum with infliximab in a child with Crohn disease. J Pediatr Gastroenterol Nutr 2002; 34: 558-60
-
(2002)
J Pediatr Gastroenterol Nutr
, vol.34
, pp. 558-560
-
-
Batres, L.A.1
Mamula, P.2
Baldassano, R.N.3
-
89
-
-
33750321159
-
Uveitis: Advances in understanding of pathogenesis and treatment
-
Read RW. Uveitis: advances in understanding of pathogenesis and treatment. Curr Rheumatol Rep 2006; 8: 260-6
-
(2006)
Curr Rheumatol Rep
, vol.8
, pp. 260-266
-
-
Read, R.W.1
-
90
-
-
31644442632
-
Retrospective case review of pediatric patients with uveitis treated with infliximab
-
Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 2006; 113: 308-14
-
(2006)
Ophthalmology
, vol.113
, pp. 308-314
-
-
Rajaraman, R.T.1
Kimura, Y.2
Li, S.3
-
91
-
-
33745581724
-
Juvenile idiopathic arthritis: An update on clinical and therapeutic approaches
-
Quarta L, Corrado A, Melillo N, et al. Juvenile idiopathic arthritis: an update on clinical and therapeutic approaches. Ann Ital Med Int 2005; 20: 211-7
-
(2005)
Ann Ital Med Int
, vol.20
, pp. 211-217
-
-
Quarta, L.1
Corrado, A.2
Melillo, N.3
-
93
-
-
33645321124
-
Granulomatous pneumonitis, sclerosing cholangitis, and pancreatitis in a child with Crohn disease: Response to infliximab
-
Silbermintz A, Krishnan S, Banquet A, et al. Granulomatous pneumonitis, sclerosing cholangitis, and pancreatitis in a child with Crohn disease: response to infliximab. J Pediatr Gastroenterol Nutr 2006; 42: 324-6
-
(2006)
J Pediatr Gastroenterol Nutr
, vol.42
, pp. 324-326
-
-
Silbermintz, A.1
Krishnan, S.2
Banquet, A.3
-
94
-
-
0037029430
-
Treatment of active anky-losing spondylitis with infliximab: A randomised controlled multicentre trial
-
Braun J, Brandt J, Listing J, et al. Treatment of active anky-losing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-93
-
(2002)
Lancet
, vol.359
, pp. 1187-1193
-
-
Braun, J.1
Brandt, J.2
Listing, J.3
-
95
-
-
0034715977
-
Crohn's disease associated with spondyloarthropathy: Effect of TNF-alpha blockade with infliximab on articular symptoms
-
Van den Bosch F, Kruithof E, De Vos M, et al. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356: 1821-2
-
(2000)
Lancet
, vol.356
, pp. 1821-1822
-
-
Van den Bosch, F.1
Kruithof, E.2
De Vos, M.3
-
98
-
-
29444445452
-
Management of recent onset Crohn's Disease: A controlled, randomized trial comparing step-up and top-down therapy [abstract]
-
Hommes D, Baert F, van Assche G, et al. Management of recent onset Crohn's Disease: a controlled, randomized trial comparing step-up and top-down therapy [abstract]. Gastroenterology 2005; 129: 371
-
(2005)
Gastroenterology
, vol.129
, pp. 371
-
-
Hommes, D.1
Baert, F.2
van Assche, G.3
-
99
-
-
33747337737
-
Biological therapy in the management of recent-onset Crohns disease: Why, when and how?
-
Löwenberg M, Peppelenbosch M, Hommes D. Biological therapy in the management of recent-onset Crohns disease: why, when and how? Drugs 2006; 66: 1431-9
-
(2006)
Drugs
, vol.66
, pp. 1431-1439
-
-
Löwenberg, M.1
Peppelenbosch, M.2
Hommes, D.3
-
100
-
-
0037434552
-
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn disease
-
Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn disease. N Engl J Med 2003; 348: 601-8
-
(2003)
N Engl J Med
, vol.348
, pp. 601-608
-
-
Baert, F.1
Noman, M.2
Vermeire, S.3
-
101
-
-
0037379792
-
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn disease: A randomized controlled trial
-
Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24
-
(2003)
Gastroenterology
, vol.124
, pp. 917-924
-
-
Farrell, R.J.1
Alsahli, M.2
Jeen, Y.T.3
-
102
-
-
0038109994
-
Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn disease: A prospective cohort study
-
Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn disease: a prospective cohort study. Gastroenterology 2003; 125: 32-9
-
(2003)
Gastroenterology
, vol.125
, pp. 32-39
-
-
Vermeire, S.1
Noman, M.2
Van Assche, G.3
-
103
-
-
0038649858
-
The incidence and management of infusion reactions to infliximab: A large center experience
-
Cheifetz A, Smedley M, Martin S. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24
-
(2003)
Am J Gastroenterol
, vol.98
, pp. 1315-1324
-
-
Cheifetz, A.1
Smedley, M.2
Martin, S.3
-
104
-
-
2342538439
-
Infliximab infusion reactions: Desensitizing ourselves to the danger
-
Persley KM. Infliximab infusion reactions: desensitizing ourselves to the danger. Inflamm Bowel Dis 2004; 10: 62-3
-
(2004)
Inflamm Bowel Dis
, vol.10
, pp. 62-63
-
-
Persley, K.M.1
-
105
-
-
0037259135
-
Safety and corticosteroid-sparing experience using infliximab for Crohn disease at a pediatric inflammatory bowel disease center
-
Stephens MC, Shepanski MA, Mamula P, et al. Safety and corticosteroid-sparing experience using infliximab for Crohn disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003; 98: 104-11
-
(2003)
Am J Gastroenterol
, vol.98
, pp. 104-111
-
-
Stephens, M.C.1
Shepanski, M.A.2
Mamula, P.3
-
106
-
-
0035344608
-
Efficacy and safety of repeated infliximab infusions for Crohn disease: 1-year clinical experience
-
Cohen RD. Efficacy and safety of repeated infliximab infusions for Crohn disease: 1-year clinical experience. Inflamm Bowel Dis 2001; 7 Suppl. 1: S17-22
-
(2001)
Inflamm Bowel Dis
, vol.7
, Issue.SUPPL. 1
-
-
Cohen, R.D.1
-
107
-
-
0033634684
-
Infliximab in Crohn disease: First anniversary clinical experience
-
Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn disease: first anniversary clinical experience. Am J Gastroenterol 2000; 95: 3469-77
-
(2000)
Am J Gastroenterol
, vol.95
, pp. 3469-3477
-
-
Cohen, R.D.1
Tsang, J.F.2
Hanauer, S.B.3
-
108
-
-
3543106683
-
Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab
-
Miele E, Markowitz JE, Mamula P, et al. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 2004; 38: 502-8
-
(2004)
J Pediatr Gastroenterol Nutr
, vol.38
, pp. 502-508
-
-
Miele, E.1
Markowitz, J.E.2
Mamula, P.3
-
109
-
-
0036081770
-
Infliximab retreatment in adults and children with Crohn disease: Risk factors for the development of delayed severe systemic reaction
-
Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002; 97: 1408-14
-
(2002)
Am J Gastroenterol
, vol.97
, pp. 1408-1414
-
-
Kugathasan, S.1
Levy, M.B.2
Saeian, K.3
-
110
-
-
33645471164
-
What's new: Innovative concepts in inflammatory bowel disease
-
Sandborn WJ. What's new: innovative concepts in inflammatory bowel disease. Colorectal Dis 2006; 8 Suppl. 1: 3-9
-
(2006)
Colorectal Dis
, vol.8
, Issue.SUPPL. 1
, pp. 3-9
-
-
Sandborn, W.J.1
-
111
-
-
4344717441
-
-
Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004; 53: 1366-73
-
Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004; 53: 1366-73
-
-
-
-
112
-
-
0037379757
-
Preventing antibodies to infliximab in patients with Crohn disease: Optimize not immunize
-
Sandborn WJ. Preventing antibodies to infliximab in patients with Crohn disease: optimize not immunize. Gastroenterology 2003; 124: 1140-5
-
(2003)
Gastroenterology
, vol.124
, pp. 1140-1145
-
-
Sandborn, W.J.1
-
113
-
-
18944367848
-
Premedication and infusion reactions with infliximab: Results from a pediatric inflammatory bowel disease consortium
-
Jacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 2005; 11: 442-6
-
(2005)
Inflamm Bowel Dis
, vol.11
, pp. 442-446
-
-
Jacobstein, D.A.1
Markowitz, J.E.2
Kirschner, B.S.3
-
114
-
-
13144265888
-
Safety of infliximab treatment in pediatric patients with inflammatory bowel disease
-
Friesen CA, Calabro C, Christenson K, et al. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004; 39: 265-9
-
(2004)
J Pediatr Gastroenterol Nutr
, vol.39
, pp. 265-269
-
-
Friesen, C.A.1
Calabro, C.2
Christenson, K.3
-
115
-
-
0000658017
-
Infliximab infusion reactions: The influence of sex and drugs
-
Han PD, Cohen RD, Motamedi F, et al. Infliximab infusion reactions: the influence of sex and drugs. Gastroenterology 2002; 122 Suppl. 4: A612
-
(2002)
Gastroenterology
, vol.122
, Issue.SUPPL. 4
-
-
Han, P.D.1
Cohen, R.D.2
Motamedi, F.3
-
116
-
-
22844450941
-
A prospective trial of infliximab therapy for refractory uveitis: Preliminary safety and efficacy outcomes
-
Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005; 123: 903-12
-
(2005)
Arch Ophthalmol
, vol.123
, pp. 903-912
-
-
Suhler, E.B.1
Smith, J.R.2
Wertheim, M.S.3
-
117
-
-
0242499967
-
Development of antinuclear antibodies and its clinical impact in patients with Crohn disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab)
-
Garcia-Planella E, Domenech E, Esteve-Comas M, et al. Development of antinuclear antibodies and its clinical impact in patients with Crohn disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab). Eur J Gastroenterol Hepatol 2003; 15: 351-4
-
(2003)
Eur J Gastroenterol Hepatol
, vol.15
, pp. 351-354
-
-
Garcia-Planella, E.1
Domenech, E.2
Esteve-Comas, M.3
-
118
-
-
0037405058
-
Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab
-
McIlwain L, Carter JD, Bin-Sagheer S, et al. Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. J Clin Gastroenterol 2003; 36: 411-3
-
(2003)
J Clin Gastroenterol
, vol.36
, pp. 411-413
-
-
McIlwain, L.1
Carter, J.D.2
Bin-Sagheer, S.3
-
119
-
-
0037247042
-
Infusion reactions to infliximab in children and adolescents: Frequency, outcome and a predictive model
-
Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003; 17: 75-84
-
(2003)
Aliment Pharmacol Ther
, vol.17
, pp. 75-84
-
-
Crandall, W.V.1
Mackner, L.M.2
-
120
-
-
0035007087
-
Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction
-
Puchner TC, Kugathasan S, Kelly KJ, et al. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 2001; 7: 34-7
-
(2001)
Inflamm Bowel Dis
, vol.7
, pp. 34-37
-
-
Puchner, T.C.1
Kugathasan, S.2
Kelly, K.J.3
-
121
-
-
0345609037
-
Characterization of tumor necrosis factor-deficient mice
-
Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A 1997; 94: 8093-8
-
(1997)
Proc Natl Acad Sci U S A
, vol.94
, pp. 8093-8098
-
-
Marino, M.W.1
Dunn, A.2
Grail, D.3
-
122
-
-
0347991877
-
The safety profile of infliximab in patients with Crohn disease: The Mayo clinic experience in 500 patients
-
Colombel JF, Loftus Jr EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31
-
(2004)
Gastroenterology
, vol.126
, pp. 19-31
-
-
Colombel, J.F.1
Loftus Jr, E.V.2
Tremaine, W.J.3
-
124
-
-
24144479466
-
Increased risk for demyelinating diseases in patients with inflammatory bowel disease
-
Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005; 129: 819-26
-
(2005)
Gastroenterology
, vol.129
, pp. 819-826
-
-
Gupta, G.1
Gelfand, J.M.2
Lewis, J.D.3
-
125
-
-
33644875213
-
TNF-alpha inhibitors and congestive heart failure
-
Behnam SM, Behnam SE, Koo JY. TNF-alpha inhibitors and congestive heart failure. Skinmed 2005; 4: 363-8
-
(2005)
Skinmed
, vol.4
, pp. 363-368
-
-
Behnam, S.M.1
Behnam, S.E.2
Koo, J.Y.3
-
126
-
-
0036255224
-
Possible activation of an intramyocardial inflammatory process (Staphylococcus aureus) after treatment with infliximab in a boy with Crohn disease
-
Reichardt P, Dahnert I, Tiller G, et al. Possible activation of an intramyocardial inflammatory process (Staphylococcus aureus) after treatment with infliximab in a boy with Crohn disease. Eur J Paed 2002; 161: 281-3
-
(2002)
Eur J Paed
, vol.161
, pp. 281-283
-
-
Reichardt, P.1
Dahnert, I.2
Tiller, G.3
-
127
-
-
1842833370
-
Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis
-
Armbrust W, Kamphuis SS, Wolfs TW, et al. Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology 2004; 43: 527-9
-
(2004)
Rheumatology
, vol.43
, pp. 527-529
-
-
Armbrust, W.1
Kamphuis, S.S.2
Wolfs, T.W.3
-
128
-
-
0037148920
-
Tuberculosis and treatment with infliximab
-
Myers A, Clark J, Foster H. Tuberculosis and treatment with infliximab. N Engl J Med 2002; 346: 623-6
-
(2002)
N Engl J Med
, vol.346
, pp. 623-626
-
-
Myers, A.1
Clark, J.2
Foster, H.3
-
129
-
-
0035846326
-
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
-
Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104
-
(2001)
N Engl J Med
, vol.345
, pp. 1098-1104
-
-
Keane, J.1
Gershon, S.2
Wise, R.P.3
-
130
-
-
33750485302
-
Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor
-
Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006; 2: 602-10
-
(2006)
Nat Clin Pract Rheumatol
, vol.2
, pp. 602-610
-
-
Winthrop, K.L.1
-
131
-
-
1842479974
-
High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy
-
Mow WS, Abreu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004; 2: 309-13
-
(2004)
Clin Gastroenterol Hepatol
, vol.2
, pp. 309-313
-
-
Mow, W.S.1
Abreu-Martin, M.T.2
Papadakis, K.A.3
-
132
-
-
33646147141
-
Serious infections and mortality in association with therapies for Crohn disease: TREAT registry
-
Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30
-
(2006)
Clin Gastroenterol Hepatol
, vol.4
, pp. 621-630
-
-
Lichtenstein, G.R.1
Feagan, B.G.2
Cohen, R.D.3
-
133
-
-
33646696885
-
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
-
Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85
-
(2006)
JAMA
, vol.295
, pp. 2275-2285
-
-
Bongartz, T.1
Sutton, A.J.2
Sweeting, M.J.3
-
134
-
-
0037344897
-
Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine
-
Navarro JT, Ribera JM, Mate JL, et al. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma 2003; 44: 531-3
-
(2003)
Leuk Lymphoma
, vol.44
, pp. 531-533
-
-
Navarro, J.T.1
Ribera, J.M.2
Mate, J.L.3
-
135
-
-
30944442404
-
Infliximab and newly diagnosed neoplasia in Crohn's disease: A multicentre matched pair study
-
Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006; 55: 228-33
-
(2006)
Gut
, vol.55
, pp. 228-233
-
-
Biancone, L.1
Orlando, A.2
Kohn, A.3
-
136
-
-
33746345358
-
Risks and benefits of infliximab for the treatment of Crohn's disease
-
Siegel CA, Hur C, Korzenik JR. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1017-24
-
(2006)
Clin Gastroenterol Hepatol
, vol.4
, pp. 1017-1024
-
-
Siegel, C.A.1
Hur, C.2
Korzenik, J.R.3
-
137
-
-
13944252969
-
Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease
-
Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005; 40: 220-2
-
(2005)
J Pediatr Gastroenterol Nutr
, vol.40
, pp. 220-222
-
-
Thayu, M.1
Markowitz, J.E.2
Mamula, P.3
-
138
-
-
33846592386
-
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease
-
Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265-7
-
(2007)
J Pediatr Gastroenterol Nutr
, vol.44
, pp. 265-267
-
-
Mackey, A.C.1
Green, L.2
Liang, L.C.3
|